Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Peters, Solange; Ross Camidge, D.; T. Shaw, Alice; M. Gadgeel, Shirish; Seok Ahn, Jin; Kim, Dong‐Wan; Ignatius Ou, Sai‐Hong; Pérol, M.; Dziadziuszko, Rafał; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noé, Johannes; N. Morcos, Peter; Mok, Tony

doi:10.1056/nejmoa1704795

Public

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Jun 6, 2017

Authors:

Solange Peters

D. Ross Camidge

Alice T. Shaw

Abstract

BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously...

Subject

Alectinib

Crizotinib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!